Sign In
Buy MMSI
$67.27
+0.770 (+1.16%)
At Close: Jun 23, 2026
Boston Scientific (BSX) Receives a Hold from Oppenheimer
04:06am, Thursday, 30'th Apr 2020
In a report released today, Steven Lichtman from Oppenheimer maintained a Hold rating on Boston Scientific (BSX), with a price target of $41.00. The
Boston Scientific (BSX) Receives a Hold from Oppenheimer
04:06am, Thursday, 30'th Apr 2020
In a report released today,
Steven Lichtman
from Oppenheimer maintained a
Hold
rating on Boston Scientific (
BSX
–
Research Report
), with a price target of
$41.00
. The company’s shares closed la
Dexcom (DXCM) Received its Third Buy in a Row
11:28am, Wednesday, 29'th Apr 2020
According to TipRanks.com, Lichtman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.1% and a 49.5% success rate.
Dexcom (DXCM) Received its Third Buy in a Row
11:28am, Wednesday, 29'th Apr 2020
According to TipRanks.com, Lichtman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Zimmer Biomet Holdings (ZBH) Received its Third Buy in a Row
09:37am, Wednesday, 29'th Apr 2020
After Wells Fargo and Goldman Sachs gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received another Buy, this time from
Zimmer Biomet Holdings (ZBH) Received its Third Buy in a Row
09:37am, Wednesday, 29'th Apr 2020
After Wells Fargo and Goldman Sachs gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received
Zimmer Biomet Holdings (ZBH) Received its Third Buy in a Row
09:45am, Tuesday, 28'th Apr 2020
After Wells Fargo and Goldman Sachs gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received another Buy, this time from
Zimmer Biomet Holdings (ZBH) Received its Third Buy in a Row
09:45am, Tuesday, 28'th Apr 2020
After Wells Fargo and Goldman Sachs gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received
Tandem Diabetes Care (TNDM) Gets a Buy Rating from Raymond James
06:17pm, Monday, 27'th Apr 2020
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Tandem Diabetes Care (TNDM), with a price target of $81.00. The
Tandem Diabetes Care (TNDM) Gets a Buy Rating from Raymond James
06:17pm, Monday, 27'th Apr 2020
In a report released today,
Jayson Bedford
from Raymond James maintained a
Buy
rating on Tandem Diabetes Care (
TNDM
–
Research Report
), with a price target of
$81.00
. The company’s shares close
Raymond James Maintains a Buy Rating on Insulet (PODD)
06:17pm, Monday, 27'th Apr 2020
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Insulet (PODD), with a price target of $220.00. The company's
Analysts Offer Insights on Healthcare Companies: Flexion Therapeutics (FLXN) and Dexcom (DXCM)
06:15pm, Monday, 27'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics (FLXN) and Dexcom (DXCM) with bullish
Analysts Offer Insights on Healthcare Companies: Flexion Therapeutics (NASDAQ: FLXN) and Dexcom (NASDAQ: DXCM)
06:15pm, Monday, 27'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics (
FLXN
–
Research Report
) and Dexcom (
DXCM
–
Research Report
) with bullish
Raymond James Boosts Merit Medical Systems (NASDAQ:MMSI) Price Target to $46.00
10:54am, Monday, 27'th Apr 2020
Merit Medical Systems (NASDAQ:MMSI) had its price objective hoisted by Raymond James from $44.00 to $46.00 in a research report released on Friday morning, BenzingaRatingsTable reports. Raymond James
Piper Sandler Equities Analysts Decrease Earnings Estimates for Merit Medical Systems, Inc. (NASDAQ:MMSI)
07:58am, Monday, 27'th Apr 2020
Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities researchers at Piper Sandler lowered their FY2021 earnings estimates for shares of Merit Medical Systems in a research note issued on Thursday, A
